Fundsmith Reduces $79M in Catalyst Pharmaceuticals, Inc. ($CPRX)

Fundsmith has significantly reduced its position in Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) according to its latest 13F filing with the SEC. The fund sold 2,518,920 shares, cutting its stake by about 74.9% to 844,887 shares, now valued at approximately $26.5 million as of the reporting period ending May 15, 2026.

What Changed in Fundsmith's Catalyst Pharmaceuticals Position

Fundsmith's decision to cut its stake in Catalyst Pharmaceuticals marks a substantial portfolio shift. Previously holding 3,363,807 shares, the fund now holds 844,887 shares after selling 2,518,920 shares. This reduction translates to a 74.9% decrease in its holdings, reflecting a change in investment strategy or outlook on the company.

Other Institutional Activity in Catalyst Pharmaceuticals

Other major funds have also adjusted their positions in Catalyst Pharmaceuticals. BlackRock, Inc. increased its holdings by 147,749 shares, bringing its total to 18,774,530 shares valued at about $464.9 million. State Street Corp reduced its position by 44,562 shares, now holding 6,863,060 shares worth $169.9 million. Meanwhile, Vanguard Capital Management LLC established a new position with 5,122,666 shares valued at approximately $126.8 million. American Century Companies Inc boosted its stake by 1,113,145 shares to 4,138,416, valued at $102.5 million. Deerfield Management Company, L.P. trimmed its holdings by 967,561 shares, leaving it with 3,943,600 shares worth $97.6 million.

Catalyst Pharmaceuticals Stock Snapshot

Shares of Catalyst Pharmaceuticals are trading at around $31.36. The company has a market cap of $3.84 billion and a P/E ratio of 18.13. Its stock has fluctuated between a 52-week low of $19.05 and a high of $32.56. The 50-day moving average stands at $29.19, while the 200-day moving average is $24.21. Catalyst maintains a strong financial position with a current ratio of 7.10 and a quick ratio of 6.70.

Recent Earnings

Catalyst Pharmaceuticals reported $596.96 million in revenue, reflecting a 5.6% growth. The company's earnings per share (EPS) were $1.73, with a net margin of 37.1% and a return on equity (ROE) of 24.5%. Investors can look forward to the next earnings report scheduled for August 5, 2026.

Insider Buying and Selling at Catalyst Pharmaceuticals, Inc.

Recent insider transactions at Catalyst Pharmaceuticals include activity by Chief Medical Officer William Andrews. On June 3, 2026, Andrews bought 3,052 shares and sold 743 shares. Chief HR Officer Gregg Russo also made transactions, buying and selling 687 shares on February 17, 2026.

Analysts Set New Price Targets

HC Wainwright & Co. downgraded Catalyst Pharmaceuticals to a hold rating with a price target of $31.50 on May 28, 2026. Similarly, Citigroup downgraded the stock to a hold with the same price target on May 8, 2026. The consensus among analysts is a hold rating, with a target mean price of $31.67 based on three analyst opinions.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida. It focuses on developing and commercializing medicines for rare diseases. The company offers treatments like Firdapse for Lambert-Eaton myasthenic syndrome (LEMS) and Fycompa for seizures. Led by CEO Richard John Daly, Catalyst operates with a team of 182 employees.

Bottom Line

Fundsmith's substantial reduction in Catalyst Pharmaceuticals highlights a significant change in its investment strategy. While the stock maintains a solid market position, the company's future performance will be closely watched by investors. It's important to remember that 13F filings are backward-looking and may not reflect current positions.